We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
Read MoreHide Full Article
Key Takeaways
BSX's Endoscopy business generated $2.16B in sales in the first nine months of 2025, or 15% of total revenues.
BSX operates in an $8B endoscopy market growing nearly 6%, with plans to outpace growth and expand margins.
BSX's endoscopy portfolio spans four segments, each positioned as a meaningful and independent growth driver.
Boston Scientific’s (BSX - Free Report) Endoscopy business is a core component of its MedSurg segment, developing and manufacturing devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative, less invasive technologies. In the first nine months of 2025, net Endoscopy sales totaled $2.16 billion, representing 15% of the company’s consolidated sales. The business currently operates in an $8 billion market growing around 6% across the 2026-2028 long-range plan, with management aiming to outpace market growth while delivering accretive operating margins.
The company serves a broad endoscopy category, segmented into four areas, each representing an independent and meaningful part of the portfolio. The first area is the pancreaticobiliary, where Boston Scientific has a long history of creating markets with products like SpyGlass, EXALT D and AXIOS. In terms of the roadmap, the company will launch a capital platform next year that will allow it to introduce some enhanced imaging technologies, with AI, into some of those single-use scopes.
Endoluminal surgery is another key franchise for Boston Scientific, with innovations like MANTIS and OverStitch. The shift from operating room into endoscopic therapies has largely been enabled by the development of improved tools, including better cutting, closure and suturing tools, supporting constant progress in this field.
Endobariatrics, an endoscopic approach to reduce the volume of the stomach, is the company’s current adjacency focus. The newly launched Endura Weight Loss Solutions are a range of minimally invasive weight loss procedures that target the attractive obesity market opportunity. Lastly, Boston Scientific’s core endoscopy franchise addresses GI strictures and bleeds, infection prevention and covers a whole host of families of products that help support those and continue to deliver profitable growth back to the division.
Update From Boston Scientific’s Peers: ABT and EW
Abbott (ABT - Free Report) has received the FDA’s approval for the Volt pulsed field ablation system to treat patients battling atrial fibrillation (AFib). The approval was based on Abbott’s VOLT-AF IDE study, which showed that the system demonstrated clinically meaningful performance in both safety and effectiveness in paroxysmal atrial fibrillation (PAF) and persistent AFib (PersAF) patient groups.
Edwards Lifesciences’ (EW - Free Report) SAPIEN M3 mitral valve replacement system became the first transcatheter therapy utilizing a transseptal approach to receive the FDA’s approval for the treatment of mitral regurgitation (MR). The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is indicated for the treatment of symptomatic moderate-to-severe or severe MR in patients who are deemed unsuitable for surgery or transcatheter edge-to-edge repair (TEER) therapy by a multidisciplinary heart team.
BSX Price Performance, Valuation and Estimates
In the past year, Boston Scientific shares have climbed 5.5% compared with the industry’s 0.1% rise.
Image Source: Zacks Investment Research
BSX shares are trading at a forward, five-year Price-to-Earnings (P/E) ratio of 27.90, above its median and the industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend.
Image: Bigstock
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
Key Takeaways
Boston Scientific’s (BSX - Free Report) Endoscopy business is a core component of its MedSurg segment, developing and manufacturing devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative, less invasive technologies. In the first nine months of 2025, net Endoscopy sales totaled $2.16 billion, representing 15% of the company’s consolidated sales. The business currently operates in an $8 billion market growing around 6% across the 2026-2028 long-range plan, with management aiming to outpace market growth while delivering accretive operating margins.
The company serves a broad endoscopy category, segmented into four areas, each representing an independent and meaningful part of the portfolio. The first area is the pancreaticobiliary, where Boston Scientific has a long history of creating markets with products like SpyGlass, EXALT D and AXIOS. In terms of the roadmap, the company will launch a capital platform next year that will allow it to introduce some enhanced imaging technologies, with AI, into some of those single-use scopes.
Endoluminal surgery is another key franchise for Boston Scientific, with innovations like MANTIS and OverStitch. The shift from operating room into endoscopic therapies has largely been enabled by the development of improved tools, including better cutting, closure and suturing tools, supporting constant progress in this field.
Endobariatrics, an endoscopic approach to reduce the volume of the stomach, is the company’s current adjacency focus. The newly launched Endura Weight Loss Solutions are a range of minimally invasive weight loss procedures that target the attractive obesity market opportunity. Lastly, Boston Scientific’s core endoscopy franchise addresses GI strictures and bleeds, infection prevention and covers a whole host of families of products that help support those and continue to deliver profitable growth back to the division.
Update From Boston Scientific’s Peers: ABT and EW
Abbott (ABT - Free Report) has received the FDA’s approval for the Volt pulsed field ablation system to treat patients battling atrial fibrillation (AFib). The approval was based on Abbott’s VOLT-AF IDE study, which showed that the system demonstrated clinically meaningful performance in both safety and effectiveness in paroxysmal atrial fibrillation (PAF) and persistent AFib (PersAF) patient groups.
Edwards Lifesciences’ (EW - Free Report) SAPIEN M3 mitral valve replacement system became the first transcatheter therapy utilizing a transseptal approach to receive the FDA’s approval for the treatment of mitral regurgitation (MR). The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is indicated for the treatment of symptomatic moderate-to-severe or severe MR in patients who are deemed unsuitable for surgery or transcatheter edge-to-edge repair (TEER) therapy by a multidisciplinary heart team.
BSX Price Performance, Valuation and Estimates
In the past year, Boston Scientific shares have climbed 5.5% compared with the industry’s 0.1% rise.
Image Source: Zacks Investment Research
BSX shares are trading at a forward, five-year Price-to-Earnings (P/E) ratio of 27.90, above its median and the industry average.
Image Source: Zacks Investment Research
Earnings estimates for Boston Scientific are showing an upward trend.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.